Anetumab Ravtansine
Ovarian Serous Adenocarcinoma
Explore 90 assets in Ovarian Serous Adenocarcinoma →Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
antibody_drug_conjugate
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03587311CT.gov Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ovarian Serous Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Anetumab Ravtansine (this asset) | National Cancer Institute (NCI) | P2 | CCC · 53 |
| Carboplatin | National Cancer Institute (NCI) | P3 | BBB |
| Cyclophosphamide | Roswell Park Cancer Institute | P2 | BB |
| Olaparib | Institute of Cancer Research, United Kingdom | P3 | BB |
| Letrozole | Memorial Sloan Kettering Cancer Center | P3 | BB |
| Adriamycin | National Cancer Institute (NCI) | P3 | BB |
| Defactinib | Verastem, Inc. | P3 | BB |
| Nogitecan | National Cancer Institute (NCI) | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | Genelux Corporation | P3 | BB |
+42 more in the Ovarian Serous Adenocarcinoma cohort
Other indications for Anetumab Ravtansine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Ovarian Endometrioid Adenocarcinoma | — | P2 | CCC · 53 |
| Fallopian Tube Endometrioid Adenocarcinoma | — | P2 | CCC · 53 |
| Fallopian Tube Serous Adenocarcinoma | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Anetumab Ravtansine in Ovarian Serous Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/anetumab-ravtansine-ovarian-serous-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →